







Xian Wu, Hang Xiao et al. 
A metabolite of nobiletin,  4' -demethylnobiletin and 
atorvastatin synergistically inhibits human colon cancer cell 






Linking the chemistry and physics of food with health and nutrition
This is an Accepted Manuscript, which has been through the  
Royal Society of Chemistry peer review process and has been 
accepted for publication.
Accepted Manuscripts are published online shortly after acceptance, 
before technical editing, formatting and proof reading. Using this free 
service, authors can make their results available to the community, in 
citable form, before we publish the edited article. We will replace this 
Accepted Manuscript with the edited and formatted Advance Article as 
soon as it is available.
You can find more information about Accepted Manuscripts in the 
Information for Authors.
Please note that technical editing may introduce minor changes to the 
text and/or graphics, which may alter content. The journal’s standard 
Terms & Conditions and the Ethical guidelines still apply. In no event 
shall the Royal Society of Chemistry be held responsible for any errors 
or omissions in this Accepted Manuscript or any consequences arising 




This article can be cited before page numbers have been issued, to do this please use:  R. B. Medina, M. I.
Russo, A. Marquez, H. M. Herrera, M. C. Abeijón-Mukdsi, L. Saavedra, E. M. Hebert and P. Gauffin-Cano,
Food Funct., 2020, DOI: 10.1039/D0FO00730G.
1
Oral administration of Lactobacillus fermentum CRL1446 improves biomarkers of Metabolic 
Syndrome in mice fed a high-fat diet supplemented with wheat bran
M. Russo1, A. Marquez1, H. Herrera2, C. Abeijon-Mukdsi1, L. Saavedra1, E. Hebert1,  P. Gauffin-
Cano1*, R. Medina1,3*
1Centro de Referencia para Lactobacilos (CERELA)-CONICET, Chacabuco 145, T4000ILC, San 
Miguel de Tucumán, Tucumán, Argentina; 
2 Facultad de Bioquímica, Química y Farmacia, Universidad Nacional de Tucumán, Ayacucho 471, 
T4000INI, San Miguel de Tucumán, Tucumán, Argentina. 
3 Facultad de Agronomía y Zootecnia, Universidad Nacional de Tucumán, Avda. Pte. N. Kirchner 
1900, T4000INH, San Miguel de Tucumán, Tucumán, Argentina. 
The first two authors have contributed equally to this work.
*Corresponding authors:  R. Medina (rmedina@cerela.org.ar), P. Gauffin-Cano 
(pgauffin@cerela.org.ar)
Tel.: 54-381-4311720. Fax: +54-381-422 3565, Int. 130


































































This work aimed to evaluate the effect of oral administration of probiotic Lactobacillus (L.) 
fermentum CRL1446, with feruloyl esterase (FE) activity, on metabolic biomarkers and intestinal 
microbiota of mice with high fat diet-induced Metabolic Syndrome (MS) and supplemented with 
wheat bran as a source of esterified ferulic acid. Six-week-old male Swiss albino mice developed 
the components of MS when fed with high fat diet supplemented with wheat bran (HFD+WB) for 
14 weeks. Positive impact of L. fermentum CRL1446 administration on these animals was reflected 
in a decrease in body weight gain and adiposity index compared to the animals that did not receive 
the probiotic strain. In addition, a decrease in plasma leptin levels, improvement of inflammatory 
profile, reduction of fatty infiltration in hepatocytes and modification of lipid profile (increased 
HDL-cholesterol and decreased LDL-cholesterol and triglyceride levels) were observed. On the 
other hand, L. fermentum CRL1446 reduced fasting glucose and insulin levels, improving the 
HOMA index in mice with MS. Postprandial glucose levels were also reduced in the oral glucose 
tolerance test. Consumption of L. fermentum CRL1446 with HFD+WB (HFD+WB-Lf mice group) 
had a great impact on host metabolism, modulating intestinal microbiota, with an increase in 
Bacteroidetes and a decrease in Firmicutes abundance being observed. Increased intestinal FE 
activity, improved oxidative status and increased abundance of 3-hydroxyphenylpropionic acid and 
butyric acid concentration in colonic content, were also demonstrated in HFD+WB-Lf mice. 
Results obtained suggest that supplementation with L. fermentum CRL1446 enhances beneficial 
effects of a bran diet, attenuating the risk factors associated with MS.
Keywords: Lipid lowering effect, hypoglycemic effect, feruloyl esterase, postbiotic, metabolic 
syndrome.


































































Metabolic syndrome (MS) is characterized by the presence of at least three of the following risk 
factors: central obesity, hyperglycemia, atherogenic dyslipidemia, and hypertension. Its prevalence 
in recent years has increased mainly due to changes in lifestyle, which include a greater sedentary 
behaviour and the consumption of diets rich in fats and sugars (Western diet). The MS is also 
associated with a high incidence of cardiovascular diseases and type 2 diabetes mellitus (T2DM), 
with significantly increased morbidity and mortality rates in the population1.
Regarding public health, the medical costs due to diseases related to MS are continuously 
increasing, and the effort required to reduce the percentage of body fat in individuals has become a 
global concern2. There are several strategies to reduce body weight, such as physical activity, 
calorie-restricted diets, use of medications, surgery, etc., but most of them involve high treatment 
costs, and in some cases, can generate adverse side effects. For this reason, the development of 
dietary strategies that include natural food products with probiotics and/or prebiotics has emerged 
as an alternative that could help to reduce the risk factors associated with MS, without generating 
adverse side effects on health3. 
In recent years, the interest in using probiotics, postbiotics or paraprobiotics, has emerged as an 
alternative for the prevention and treatment of pathologies related to obesity and MS, improving the 
balance of intestinal microbiota, decreasing the sensation of hunger and central adiposity, and 
improving the lipid profile and integrity of intestinal mucosa with a decrease in the inflammatory 
degree4. Some probiotic bacteria synthesize products or metabolic byproducts (postbiotics) which 
are secreted by live cells, such as enzymes and organic acids, that might also offer physiological 
benefits to the host by providing additional bioactivity5. Among the physiological functions of 
postbiotics, immunomodulation, anti-inflamatory, hypocholesterolemic, anti-obesogenic, and 
antioxidant effects are included6, 7. As probiotic microorganisms, mainly lactic acid bacteria (LAB) 
belonging to Lactobacillus genus is used. Several LAB strains can exert beneficial effects on the 
host based on enzyme activities.  In this sense, LAB with feruloyl esterase (FE) activity allow 

































































increasing the bioavailability of ferulic acid (FA) at the intestinal level, which could induce 
metabolic changes that are positive in individuals who develop MS8. The consumption of FA, a 
type of phenolic compound, has been associated with the reduction of several risk factors present in 
chronic non-communicable diseases, such as T2DM, cardiovascular, neurodegenerative 
pathologies, etc.9 Its beneficial properties are attributed to multiple bioactive functions (antioxidant, 
antimicrobial, anti-inflammatory, etc.), which depend on FA intake. However, the bioavailability of 
FA is limited because it is present in vegetable matrices in esterified form (hydroxycinnamates), 
which regulates its bioefficacy 10. Therefore, FEs play an important role in the hydrolysis of ester 
bonds and the subsequent release of FA, thus constituting a fundamental step required for its 
bioavailability and metabolism. 
In rodents, the intestinal FE activity is provided by both intestinal microbiota and epithelial cells 
11, 12. On the other hand, Filannino et al.13 affirm that bacterial FE enzymes present in the colon are 
primarily responsible for increasing the bioavailability of FA in humans. When FA is ingested in 
the dietary fiber, 90% of it reaches the colon in the form of hydroxycinnamates (ferulates). Thus the 
colonic microbiota is the main responsible for the release of FA from its conjugated forms, because 
of the breakdown of ester bonds by action of FE and its subsequent metabolism14.
This work aims to evaluate the effect of oral administration of probiotic L. fermentum CRL1446, 
with FE activity, on metabolic biomarkers and intestinal microbiota of mice with high fat diet-
induced MS and supplemented with wheat bran as a source of esterified FA.
2. Materials and Methods
2.1. Bacterial strain, culture conditions and cell suspension preparation
L. fermentum CRL1446 was obtained from the Culture Collection of the Centro de Referencia 
para Lactobacilos (CERELA, Tucumán, Argentina). This strain has FE activity and is capable of 
releasing FA from wheat bran15.  L. fermentum was maintained in de Man, Rogosa and Sharpe 

































































(MRS) broth (Britania, Buenos Aires, Argentina)16 containing 20% (v/v) glycerol at −80°C and it 
was propagated three times in MRS broth before each experimental use. For cell suspension 
preparation, L. fermentum CRL1446 was inoculated at 2% (v/v) in 50 mL of MRS broth and 
incubated at 37°C for 12 h. Cells were harvested by centrifugation (10,000 g 10 min) and washed 
twice with sterile phosphate-buffered saline (PBS) pH7. Cells were resuspended in sterile drinking 
water to achieve a concentration of 10⁹ cells/mL for animal assays.
2.2. Animal protocol
Six-week-old male Swiss albino mice (n=24) were obtained from the closed random-bred colony 
maintained at CERELA. They were housed in individual cages and were acclimated to a 
temperature of 22°C ± 2°C with a 12-h light/dark cycle. Mice were then separated into three groups 
containing 8 mice each. The groups were as follows:
1. Control group, mice receiving by gavage 100 µL of drinking water  and fed daily with a 
normal diet;
2. MS group, mice receiving by gavage 100 µL of drinking water and fed daily with a high-fat 
diet supplemented with wheat bran to 7% (w/w) (HFD+WB);
3. MS+Lf group, mice receiving by gavage 100 µl of L. fermentum CRL1446 suspension 
(resulting in a dose of 108 cells/day) and fed daily with HFD+WB.
The control group mice received a normal diet (3.1 Kcal/g, with 6.5% vegetable oil-derived Kcal) 
and drinking water ad libitum for 14 weeks. Animals from the MS and MS+Lf groups were 
acclimated for 5 days to ad libitum normal diet, after which they were fed daily with HFD+WB (5.1 
Kcal/g, with 60% lard-derived Kcal) for 14 weeks. Both diets supplied approximately 0.60 mg of 
hydroxycinnamates/day/mouse which are in their ester-linked form in wheat bran. The nutritional 
composition of normal diet and HFD+WB are listed in Supplementary Table S1.

































































The food intake and body weight of each mouse were measured every week. Body weight gain 
was expressed as follows: body weight at week 14 (g) − initial body weight (g). The food efficiency 
ratio was expressed as follows: body weight gain (g)/food consumed (g) at week 14.
Oral glucose and sucrose tolerance tests were performed after week 14 of treatment. Mice were 
fasted for 12 h, and glucose or sucrose was orally administered by gavage at a dose of 2 g/Kg. 
Blood samples were obtained by saphenous vein puncture before and after 30, 60, 90 and 120 
minutes of glucose or sucrose administration, according to Tomaro-Duchesneau et al.16. Glucose 
levels were analyzed with glucose test strips using a Glucometer from Accu-Chek Active (Roche, 
Germany). The homeostatic model assessment for insulin resistance (HOMA-IR) was calculated 
using insulin and glucose plasma values obtained at week 14 of the experimental trial 17.
At the end of the experimental period, the mice were fasted for 12 h and were anesthetized using 
an intraperitoneal injection of ketamine hydrochloride (100 mg/Kg of body weight) and xylazine 
hydrochloride (5 mg/Kg of body weight).
The experimental protocol complied with current Argentinean laws and was approved by the 
Animal Protection Committee of CERELA (CRL-BIOT-EF-2019/1A).
2.3. Biochemical assays
Blood samples were obtained from all animals (n=24) by cardiac puncture and were transferred 
into tubes containing the anticoagulant EDTA (Wiener Lab, Rosario, Argentina). Plasma was 
obtained by centrifugation (2500 ×g, 10 min) and was used for biochemical assays. Plasma glucose, 
total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride, alanine transaminase (ALT) and 
aspartate transaminase (AST) concentrations were measured by enzymatic methods using 
commercial kits (Wiener Lab, Rosario, Argentina).
Cardiovascular risk indicators (LDL-/HDL-cholesterol ratio, Triglyceride/HDL-cholesterol ratio 
and atherogenic index were calculated according to the protocol described by Millán et al. 18 and 
Vega et al. 19.

































































Plasma leptin concentrations were determined using an immunoassay kit (ELISA, DuoSet, R & 
D Systems, MN, USA). Plasma insulin levels were measured using ELISA (Mouse Insulin ELISA 
Kit, Alpco Diagnostics, USA).
Fasting plasma insulin and glucose levels were used to calculate insulin resistance using the 
homeostasis model assessment for insulin resistance (HOMA-IR) [(fasting glucose × fasting 
insulin)/22.5] 17.
2.4.  Determination of plasma cytokines
Plasma cytokine levels (TNF-α, IFN-γ, IL-6, and IL-10) were determined by flow cytometry, 
using the CBA Mouse Soluble Protein Flex Set kit (BD CA, USA).
2.5.  Determination of plasma lipoperoxidation
Lipoperoxide derivative concentrations in plasma were determined using the thiobarbituric acid 
reactive substances (TBA) methodology20.  Results were expressed as nmoles TBARS/g of proteins.
2.6.  Animal sample collection, adiposity index and liver histology
After blood collection, organs (large intestine, liver, mesenteric and epididymal fat) were 
surgically removed, washed using PBS, wiped with a paper towel and weighted.
The adiposity index was calculated using the following formula: total fat (mesenteric + 
epididymal) weight/body weight) × 100.
Liver weight was expressed as follows: liver weight (g)/body weight (100 g). Four liver samples 
from each experimental group were macrodissected, placed into plastic cassettes and fixed with 
formaldehyde solution (10% v/v in PBS, pH 7.0); the dehydrated samples were embedded in 
paraffin blocks. The paraffin blocks were sectioned at approximately 3–5 μm and were placed on 
glass slides stained with hematoxylin and eosin for subsequent histological studies.

































































The size of adipocytes in adipose tissue from each experimental group was determined 
according to the methodology described by Cano et al.21, using Carl Zeiss software - Axio Vision 
Release 4.8. Photomicrographs of adipose tissue sections from each group were taken with a 40x 
objective. The area (μm2) of each adipocyte was determined from a total of 100 adipocytes in two 
histological sections per mouse of each group. The adipocytes were grouped by size ranges 
according to their areas (A) as follows: 500≤A≤1000 μm2; 1000<A≤2000 μm2; 2000<A≤3000 μm2; 
3000<A≤4000 μm2; 4000<A≤8000 μm2. 
For determination of FE activity, ferulic acid metabolites and short-chain fatty acid levels, eight 
large intestine samples from each experimental group were aseptically removed and their contents 
were collected according to the protocol described by Abeijón Mukdsi et al. 12 and Lorenzo-
Pisarello et al.22.
2.7.  Determination of glutathione peroxidase (GPx) and glutathione reductase (GR) 
activities in liver
Four liver samples from each experimental group were homogenized (buffer volume: fresh liver 
weight, 5:1) using a mortar and pestle with 100 mM potassium phosphate buffer (pH 7.5) 
containing 1 mM EDTA and 3 mM DL-dithiothreitol23. The homogenate was centrifuged (12,000 
×g for 30 min at 4°C) and the supernatant was aliquoted and stored at −80°C, until determination of 
protein concentration and GPx and GR activities. GPx activities were determined according to the 
protocol described by Flohé and Günzle24. Results were expressed as units (U) of GPx activity/g 
liver. One unit was defined as the amount of enzyme-producing 1 nmol of oxidized NADP/minute. 
GR activities were determined according to the protocol described by Esterbauer and Gril25, by 
following the rate of NADPH oxidation at 340 nm. Results were expressed as units (U) of GR 
activity/g liver. One unit was defined as the amount of enzyme producing 1 nmol of NADP/ minute.

































































2.8.  Inhibition of α-glucosidase activity in vitro
The inhibitory capacity of α-glucosidase activity was determined using the method described by 
Li et al. 26, using p-nitrophenyl α-D-glucopyranoside as substrate. 
2.9.  Protein determination
Protein concentration was estimated by the Bradford method27, using a commercial kit (Bio-
Rad, Hercules, CA, USA). Bovine serum albumin (Sigma, St. Louis, MO, USA) was used as 
standard. 
2.10. Determination of Intestinal FE Activity
Intestinal FE activity was determined in intestinal contents according to the protocol described 
by Abeijón Mukdsi et al.12. Results were expressed as units (U) of FE activity/gram of intestinal 
content. One unit was defined as the amount of enzyme releasing 1 mmol of FA/hour.
2.11. Determination of short-chain fatty acid (SCFA) in large intestine contents
Acetic, propionic and butyric acids were determined in large intestine content according to the 
methodology described by Lorenzo-Pisarello et al.22. SCFA produced were quantified by HPLC 
(Knauer system) using an ion-exchange column (BIO-RAD Aminex HPX-87H; 300 × 7.8 mm). 
The different components were eluted with 5 mM H2SO4 at a flow rate of 0.6 mL min-1. SCFA 
concentrations were reported as mmol/g of large intestine content.
2.12. Detection of ferulic acid (FA)  metabolites in large intestine contents
The presence of FA-derived metabolites was determined in large intestine contents of mice fed 
for 14 weeks. For this purpose, 30% (w/v) intestinal homogenates were prepared in PBS pH 7. To 
extracte metabolites, aliquots of 500 μL of homogenate were acidified with 10 μL of HCl (37%) 

































































and extracted with 2 mL ethyl acetate. Samples were centrifuged (8000 x g, 10 min), and the 
organic phase was recovered and subsequently evaporated to dryness in a water bath at 40°C under 
a stream of N2. The dry residues were resuspended in 100 µL of methanol. 20 μL of each sample 
was injected into an HPLC-UV-MS system (InMetS. A., Rosario, Argentina) to detect the different 
phenolic compounds derived from FA metabolism. The conditions used were the following: Mobile 
phase: A: H2O MQ / 0.1% v/v formic acid; B: Acetonitrile / 0.1% formic acetic; Flow: 0.2 mL / 
min; Column: C18 Hypersil-GOLD, Thermo Scientific (50 x 2.1 mm; 1.9 μm particle size); 
Column temperature: 25°C; Autosampler temperature: 20°C; Detection: UV 320 nm, 265 nm + MS; 
Run time: 21 minutes.
2.13. Bacterial DNA Extraction, Sequencing, and Quantification
At the end of the 14 weeks of feeding and before the animals were slaughtered, stool samples 
from mice from each group were collected in sterile eppendorf tubes and stored at -20°C (n=3).
The DNA extraction was performed using a specific commercial kit for fecal samples (QIAamp 
DNA Stool Mini Kit, Hilden, Germany). 
A 20 μl aliquot of DNA from each sample was used for amplicon sequencing by means of a MiSeq 
Illumina sequencing platform (Shallowater, TX, USA). The V4 region of the 16S rRNA gene was 
amplified by PCR using primer pairs 515F (5′-GTGCCAGCMGCCGCGGTAA-3′) and 806R (5′-
GGACTACHVGGGTWTCTAAT-3′) according to Illumina Protocol to generate an amplicon size 
of ∼400 bp28.  Libraries were constructed by ligating sequencing adapters and indexes onto purified 
PCR products using the Nextera XT Sample Preparation Kit (Illumina, San Diego, CA, USA) 
following the manufacturer's specifications. Equimolar amounts of each of the libraries were pooled 
and they were sequenced in an Illumina MiSeq personal sequencer using a paired end-of-reading 
protocol of 400 bp in length. Quality of sequences control was performed using the QIIME 
pipeline29. Sequences were first quality filtered and screened for chimeras using the UCHIME 
algorithm implemented in USEARCH (version 6.1544; 21)30, 31 . The remaining high quality 16S 

































































rRNA gene sequences were clustered into OTUs (operational taxonomic units) at 97% similarity 
with the de novo reference OTU picking method and USEARCH (version 6.1544). Taxonomy 
assignation was performed with Bayesian RDP Classifier32, using an assignment confidence cutoff 
of 0.8. For calculation of the richness estimators, Chao 1 and the Shannon diversity indexes were 
determined using QIIME, with sample rarefaction set at 18,850 sequences per sample based on the 
sample with the least number of sequences. In addition, QIIME was also used to calculate beta 
diversity metrics among samples using weighted Unifrac distances and Bray-Curtis similarity30.
2.14. Statistical Analysis
Results are means of three independent experiments ± standard error of the mean (SE). Data 
were submitted to one-way analysis of variance (ANOVA) using SPSS version 12.0 (SPSS Inc., 
Chicago, IL, USA). Tukey’s test was used to identify statistically significant differences (P < 0.05). 
3. Results and discussion
3.1. Effects of L. fermentum CRL1446 administration on body weight gain, food efficiency 
ratio, adiposity index and leptin levels in MS mice
Body weight gain (BWG) and food efficiency ratio (FER) were augmented by the consumption 
of HFD+WB, being observed in mice from MS group, an increase of 63% and 86%, respectively 
compared to control group (Table 1). L. fermentum CRL1446 administration (MS+Lf group) caused 
a significant reduction in both parameters with respect to MS group, reaching values similar to the 
control. Values of food intake and BWG allows evaluating the ability of an organism to transform 
grams of food consumed into grams of body mass, which is known as FER. These two parameters 
are closely related to the composition of intestinal microbiota and diet33. Similar results were 
reported by Park et al.34, who observed a decrease in FER by administering a combination of two 
probiotic strains (L. curvatus HY7601 and L. plantarum KY1032) for 8 weeks to mice fed with 

































































HFD. Previous studies, which analyze the influence of Lactobacillus spp. administration on the 
BWG showed that this effect is dependent on each strain. While some species induce a decrease in 
weight, others do not affect it or induce increases35, 36. 
Mice of MS group developed obesity characterized by an increase in mesenteric and epididymal 
adipose tissue (which was reflected in a 99% higher adiposity index value, compared to control 
group). The MS+Lf group showed a 39% decrease in the adiposity index compared to MS group 
(Table 1). These results are in accordance with those of Bhathena et al.8, who observed a reduction 
in the adiposity index when L. fermentum ATCC11976, strain with FE activity, was administered to 
hamsters with MS.
Histological studies of epididymal adipose tissue revealed changes in the number and size of 
adipocytes in mice from the two experimental groups under study (Figure 1A and 1B). In the MS 
group, a high abundance (57%) of large adipocytes (4000<A≤8000 μm2) was found, while in the 
control group only 9% of adipocytes were within this range. Besides, a significant decrease in the 
amount of small-sized adipocytes (ranges between 500 and 3000 μm2) was observed in the MS 
group compared to control group. In MS+Lf group, there was an increase in the number of larger 
adipocytes (4000<A≤8000 μm2) compared to control group, however, these represented only 20% 
of the total (3 times less than in the MS group). These results showed that CRL1446 strain could 
prevent hypertrophy of adipose tissue in animals fed with HFD+WB. Other authors also reported a 
similar effect of probiotic microorganisms on adipocyte size21. The adipose tissue increase is 
considered a critical determinant of obesity and can occur through the increase in adipocyte size 
(hypertrophy) or in adipocytes number (hyperplasia)37. 
Since adipose tissue is primarily responsible for the synthesis and secretion of leptin, plasma 
levels of this hormone were dosed in mice from all groups (Table 1). Plasma leptin levels were 7-
fold higher in animals from MS group than in the control group. In MS+Lf group, leptin values 
were 3.5-fold lower than in the MS group. Leptin is secreted by adipocytes in levels proportional to 
the amount of body fat and constitutes a key peripheral signal that indicates the status of body 

































































energy stores38. Our results reflected a status of hyperleptinemia in mice from MS group, which was 
reported as a characteristic of obesity, with a status of resistance to leptin. Oral administration of L. 
fermentum CRL1446 allowed decreasing the hyperleptinemia in animals fed with HFD+WB. The 
reduction of plasma leptin levels as a consequence of the administration of probiotic 
microorganisms in diet-induced obesity models has been reported by other authors21.
3.2. Effect of L. fermentum CRL1446 administration on inflammatory status of MS mice
The inflammatory status of the animals was evaluated by determining the plasma levels of 
cytokines TNF-α, IFN-γ, IL-6 and IL-10 (Table 2). The proinflammatory cytokine levels (TNF-α, 
IFN-γ, IL-6) showed a significant increase in MS group compared to control group. In MS+Lf 
group, the levels of these cytokines were significantly reduced with respect to MS group. These 
results are consistent with those reported by other authors in animal models fed with HFD39. 
Regarding the levels of IL-10 (an anti-inflammatory cytokine), a three-fold decrease was observed 
in MS group compared to control group. In MS+Lf group, IL-10 levels were 1.5-fold higher than in 
MS group. Previous studies reported that there is a negative relationship between obesity and IL-10 
levels40. The administration of L. fermentum CRL1446 improved the inflammatory profile of 
animals that received HFD+WB, a reduction in pro-inflammatory cytokines and an increase in IL-
10 being observed.
3.3. Effect of L fermentum administration on the accumulation of fat in liver and 
transaminase activities in MS mice.
A pathology that is usually associated with MS is the accumulation of fat in the liver; therefore, 
an analysis of liver histology in animals from each group was carried out.
The results showed that mice fed with HFD+WB exhibited hepatic steatosis characterized by the 
presence of abundant vacuoles or lipid droplets of different sizes, as well as cytoplasmic granularity 

































































of hepatocytes. Ballooning and hepatocellular binucleation could also be observed. MS+Lf group 
mice showed a reduction in fatty infiltration in hepatocytes (Figure 2). The accumulation of liver fat 
is a sign of the early development of non-alcoholic fatty liver disease (NAFLD) and is associated 
with the deregulation of lipid and glucose metabolism41.
The increased activity of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
is usually associated with liver damage. In MS group, plasma levels of ALT and AST showed a 2-
fold increase compared to control group. L. fermentum administration decreased ALT and AST 
activities to values similar to those observed in the control group (Figure 3). Transaminase activities 
(ALT and AST) are considered clinical biomarkers of liver function and disease. Also, it has been 
found that the augmentation of ALT and AST levels is associated with a higher body mass index 
and abdominal obesity, even in the absence of liver disease42. Other authors have reported an 
improvement in the fatty liver when a mix of probiotics was administered to rats with steatosis, 
associating the lower accumulation of fat with the modulation of the lipid profile, leptin and 
inflammatory biomarkers43. On the other hand, Bhathena et al.42, have demonstrated the beneficial 
effect of the administration of a microorganism with FE activity (L. fermentum ATCC 11976) in a 
golden Syrian hamster NAFLD model. 
3.4. Effect of administration of L fermentum on lipid profile and cardiovascular risk 
indicators
The effect of HFD+WB and L. fermentum CRL1446 administration on plasma levels of total 
cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides were evaluated (Table 3). A 33% 
increase in total cholesterol level was observed in MS group compared to control group. Total 
cholesterol level in MS+Lf group showed no significant differences with control animals (Table 3).
The HDL-cholesterol values in MS group decreased by 22% compared to control group. The 
administration of L. fermentum CRL1446 (MS+Lf group) allowed maintaining levels similar to 
those found in the control group. Regarding to LDL-cholesterol, in MS group a 26% increase in the 

































































levels of this lipoprotein was observed compared to control group, while the administration of L. 
fermentum CRL1446 (MS+Lf) reduced LDL-cholesterol levels to values similar to those detected in 
the control group. These results were similar to those observed by Bhathena et al.8 in hamsters with 
MS treated with L. fermentun ATCC11976, strain with FE activity.
MS group showed a 56% increase in triglyceride levels compared to control group. In MS+Lf 
group, hypertriglyceridemia was reduced to values similar to the control group.
Table 3 shows the values of the cardiovascular risk indicators, which showed an approximately 2-
fold increase in the MS group compared to control group. In MS+Lf group, values lower than those 
of MS group or similar to control group were observed.  Various cardiovascular risk indicators 
(CRI) have been proposed, which have greater predictive value than the lipid fractions 
themselves18. Our results showed an increase of CRI in MS group compared to control. Mice from 
MS+Lf group presented lower values than those from MS group. Tomaro- Duchesneau et al.44 
reported similar results in MS rats treated with L. fermentum NCIMB 5221, strain with FE activity. 
Naowaboot et al.45 showed that the administration of ferulic acid in obese mice fed with HFD 
improved lipid homeostasis, probably through the modulation of lipogenic gene expression 
(SREBP1c, FAS, ACC) and stimulation of β-oxidation genes (CPT1A , PPARγ).
3.5. Effect of L. fermentum CRL1446 administration on Oral glucose tolerance test (OGTT), 
fasting glucose and insulin levels
Results show that MS group presented significantly higher blood glucose levels at all points of 
the curves with respect to control group, with values greater than 200 mg /dL after 120 min of oral 
overload, indicating insulin resistance (IR). Supplementation HFD+WB diet with L. fermentum 
CRL1446 reduced postprandial glucose levels to values similar to those observed in control group 
(Figure 4A and 4B).

































































Fasting plasma glucose and insulin levels in MS group increased by 96% and 45%, respectively, 
compared to control group, whereas in mice of the MS+Lf group, they decreased to values similar 
to control group (Table 4).
The HOMA-IR index to assess insulin resistance was approximately 3-fold higher in MS group 
than in control group. The administration of L. fermentum CRL1446 decreased the HOMA-IR index 
in MS group, to similar values to those observed in control group (Table 4).
Naowaboot et al.45 have suggested that ferulic acid could act decreasing the expression of 
hepatic enzymes of gluconeogenesis, (phosphoenolpyruvate carboxylase and glucose-6-
phosphatase), thus reducing blood glucose levels. Bhathena et al.8 reported that the administration 
of L. fermentum ATCC11976 (strain with FE activity) to hamsters with MS decreased serum insulin 
and glucose levels. The results obtained in this work also agree with those reported by Lim et al.46, 
who demonstrated that the administration of L. sakei OK67 to obese HFD-induced mice improves 
glucose tolerance.
3.6. Evaluation of the antihyperglycemic effect of Lactobacillus fermentum CRL1446
To evaluate the antihyperglycemic effect of L. fermentum CRL1446, the Oral Sucrose Tolerance 
Test (OSTT) was performed and the ability of this bacterium to inhibit α-glucosidase was 
determined. In the OSTT test, the results showed a significant increase in blood glucose levels in 
MS group at all points of the curve; while in MS+Lf group, no differences were observed with 
respect to control group. The area under the curve in MS group showed a 36% increase with respect 
to control group, while in MS+Lf group it was similar to control group (Figure 5A and 5B). 
Measuring blood glucose levels after a sucrose intake is an indirect method for assessing the ability 
of LAB strains to inhibit α-glucosidase activity. Intestinal α-glucosidases participate in the cleavage 
of sucrose with the consequent release of glucose, and its inhibition would allow maintaining lower 
blood glucose concentrations.

































































In order to verify whether the effect on glycemia observed in vivo could be attributed to the 
strain administered, an in vitro study was conducted to assess its ability to inhibit α-glucosidase 
enzyme. Results showed that L fermentum CRL1446 was able to inhibit 90.41% of α-glucosidase 
activity.  Li et al.26 reported that the administration of L. plantarum X1 with α-glucosidase 
inhibitory capacity improved risk markers in rats with DT2. Likewise, Malunga et al.47 reported that 
ferulic acid and mono and oligosaccharides (feruloylated arabinoxylan) were able to inhibit α-
glucosidase enzyme. This information suggests that the antihyperglycemic effect of L. fermentum 
CRL1446 in MS mice could be enhanced by the presence of ferulic acid in dietary bran fibers.
3.7. Effect of administration of L. fermentum CRL1446 on intestinal FE activity and oxidative 
status in MS mice
Intestinal FE activity was significantly reduced (42%) in mice from MS group compared to 
control group. Supplementation of HFD+WB with L. fermentum CRL1446, strain with FE activity, 
increased intestinal FE activity in MS+Lf group by 46%, compared to MS group (Table 5). 
However, FE activity of MS+Lf group did not reach the values observed in the control group. It 
should be noted that despite the fact that we administered a probiotic strain with FE activity, mice in 
the MS+Lf group are animals on the way to develop pathology such as MS due to their diet, while 
the control group is made up of healthy animals, so the difference in activity intestinal enzyme is 
understandable. In previous studies, Abeijón Mukdsi et al.12 reported increased FE activity in large 
intestine content in mice fed normal diet supplemented with L. fermentum CRL1446. Our results 
would indicate that L. fermentum CRL1446 could increase the bioavailability of FA from dietary 
wheat bran at the colon level, to be subsequently absorbed and metabolized, thus exerting its 
beneficial effects.
The oxidative status of mice was evaluated by determining in liver glutathione peroxidase (GPx) 
and glutathione reductase (GR) activities and plasma lipoperoxide (TBARS) concentration (Table 
5). In MS group, there was a decrease in GPx and GR activities (11% and 15%, respectively) and an 

































































increase in TBARS concentrations (48%) compared to control group. The administration of L. 
fermentum CRL1446 improved oxidative status in mice (MS+Lf group) as evidenced by an increase 
in GPx (37%) and GR (64%) activities compared to MS group. Besides, plasma TBARS levels in 
MS+Lf group showed a significant reduction with respect to MS group, maintaining similar values 
to control group (Table 5). These results indicate that CRL1446 strain is capable to improve the 
oxidative status of mice with MS.
FA shows high antioxidant activity in vitro; however, its biological effect in vivo is questionable 
due to its low degree of absorption and rapid metabolism within the host48.  Rondini et al.49 showed 
that the administration of FA to rats, in its complexed form in a natural product such as wheat bran, 
increases the half-life of FA in plasma, improving its bioavailability. Recent studies reported that 
the administration of feruloylated oligosaccharides to rats with T2DM improved the lipid profile of 
these animals more effectively compared to free FA50. The administration of LAB with FE activity 
in the diet could be a strategy to increase the bioavailability of FA in the gut, since it is gradually 
released by enzymatic hydrolysis, improving MS biomarkers.
3.8. Detection of metabolites derived from FA and quantification of short-chain fatty acids 
(SCFA) in colon contents
To verify whether the administration of CRL1446 strain improves the release of FA in the colon, 
the presence of this acid and its metabolites in colon contents was evaluated. The determination was 
semiquantitative since the abundance of each metabolite could be estimated according to the size of 
the spectral peaks (Figure S1 and Table 6). FA metabolism by intestinal microbiota enzymes 
produce bioactive compounds: dihydroferulic acid (DHF), 3,4-dihydroxyphenylpropionic acid 
(DHPPA), 3-hydroxyphenylpropionic acid (HPPA) and benzoic acid (BA) that can be absorbed and 
transported to the liver or part of them can be excreted in the feces51. It has been shown that 
bioactive phenolic compounds reach low concentrations in the plasma (in the order of μg), so the 
role of the microbiota in their metabolism is highlighted 52.

































































In all groups of animals dihydroferulic acid (DHF), 3,4-dihydroxyphenylpropionic acid 
(DHPPA) and 3-hydroxyphenylpropionic acid (HPPA) were detected (Table 6). A lower abundance 
of HPPA was observed in MS group compared to control, and an increase of this compound was 
found when L. fermentum CRL1446 was administered. These results would indicate that FA was 
bioavailable and it was metabolized and transformed into each of the above mentioned compounds, 
which is consistent with the highest intestinal FE activity observed in control and MS+Lf groups.
Similarly, Duncan et al.53 found HPPA as the main metabolite derived from FA when evaluating 
the fermentation of wheat bran by human feces. These authors, based on metagenomic studies, 
reported that wheat bran promotes an enrichment in butyric acid producing bacteria capable of 
releasing FA from the fiber (i.e., with FE activity). Thus, they postulated that the increase in 
bacteria producing butyric acid and releasing FA during the degradation of wheat bran could 
explain the beneficial health effects attributed to fiber consumption.
SCFA are produced by fermentation of diatary fiber by colonic microbiota. Therefore, SCFA 
content depends on the composition of the intestinal microbiota and the type of fermented 
substrate54.  Acetic, propionic and butyric acid concentrations in large intestine contents of mice 
from all the groups studied were determined (Figure 6). Results showed a significant reduction in 
the levels of all SCFA in MS group with respect to control. The MS+Lf group showed no 
differences in acetic and propionic acid concentrations with respect to MS group, but an increase in 
the concentration of butyric acid was observed. These results would indicate a lower metabolic 
activity of colonic microbiota in animals with MS, and that supplementation with L. fermentum 
CRL1446 causes an increase in the concentration of butyric acid with respect to MS group.
The type and concentration of SCFA produced by intestinal microbiota are important for the 
development or prevention of obesity and MS55. The most abundant SCFA in the colon are acetic, 
propionic and butyric acids, which are normally found in a molar ratio that can range from 3: 1: 1 to 
10: 2: 156. Butyrate is a key energy source for human colonocytes; there is also evidence that 
butyrate can activate intestinal gluconeogenesis through a cAMP-dependent mechanism with 

































































beneficial effects on glucose control and energy homeostasis57. Likewise, it was reported that 
butyrate protects against diet-induced obesity without suppressing food intake58. Brinkworth et al.59 
reported a decrease in SCFA, especially butyrate, in obese subjects who consumed HFD low in 
carbohydrates, compared to obese subjects who consumed a diet low in fat and enriched in 
carbohydrates and fibers.
The complex and dynamic intestinal microbial ecosystem contributes to the metabolism of 
various compounds from the diet, producing numerous metabolites. The production of specific 
metabolites, such as SCFA, is closely linked to the host's energy homeostasis56.
For this reason, it has been suggested that the modification of intestinal microbiota by the 
administration of specific LAB could influence metabolic parameters, either to counteract or favor 
the effects of the diet.
3.9. Effect of HFD+WB and L. fermentum CRL1446 administration on intestinal microbiota 
of mice
To investigate the impact of the administration of HDF+WB and L. fermentum CRL1446 on the 
composition of intestinal microbiota of mice, high performance sequencing technology (HTS) was 
used. Several indices of alpha diversity were calculated to determine whether dietary 
supplementation with L. fermentum CRL1446 was associated with a difference in the number of 
OTUs. Interestingly, significant differences were observed in the number of OTUs in the "species" 
level and in the Chao1 metrics (an accurate estimator of the number of different species or richness) 
when comparing the MS+Lf group with the control or MS group (Table 7). The results indicate a 
greater phylogenetic diversity (PD whole tree) in the mice that received L. fermentum CRL1446 
with respect to the mice to which the probiotic was not administered. No significant differences 
were observed in the alpha diversity metrics between MS and Control groups, except for the 
Shannon index that was higher in MS group (Table 7). The analysis of beta diversity using Unifrac 

































































showed a variation of the principal components (PCoA) according to the type of diet administered; 
the different clustering in the 3 groups of mice evaluated was evident (Figure 7). 
The bacterial communities in all groups were dominated by two phyla: Bacteroidetes and 
Firmicutes (Figure 8A). The relative abundance of Bacteroidetes phylum (which includes all 
Bacteroidales) was lower in MS group (31.2%) with respect to control group (85.8%), while in mice 
that received L. fermentum CRL1446 (MS+Lf group) Bacteroidetes increased (59.05%) compared 
to MS group (Figure 8A). On the other hand, the proportion of the phylum Firmicutes (which 
includes all Clostridiales and Lactobacillales) was 12.75% in control group and it increased with the 
administration of HFD+WB in the MS group (55.05%); however, when this diet was also 
supplemented with the probiotic L. fermentum CRL1446 (MS+Lf group), it was observed a 
decreased abundance of Firmicutes (36.05%) (Figure 8A).
The current vision regarding the investigation of metabolic syndrome and associated pathologies 
focuses on the study of intestinal microbiota. One of the main functions of the microbiota is its 
ability to extract energy from the diet, which is possible thanks to the role that bacteria play in 
transforming complex nutrients, such as dietary fiber, into simple sugars and short-chain fatty acids, 
avoiding their loss in stools60. It is interesting to mention that many studies indicate that 
Bacteroidetes are more abundant when maintaining a low-calorie diet61. Mice subjected to fat-rich 
Western-type diets show an increase in Firmicutes and a decrease in Bacteroidetes62. The relative 
abundance of Bacteroidetes in MS mice was lower than 50%, whereas the Firmicutes were higher 
than 50% (Figure 8A). Similar results were reported by Ley et al.63 in obese mice. In this study, the 
administration of L. fermentum CRL1446 allowed modifying the intestinal microbiota by 
counteracting the effects of HFD+WB with an increase in Bacteroidetes and a decrease in 
Firmicutes abundance. Ma et al.64 reported that FA modulates the intestinal microbiota composition 
of mice fed HFD by decreasing the proportion of Firmicutes while increasing the proportion of 
Bacteroidetes, improving non-alcoholic fatty liver disease in animals. This suggests that the 
observed effect on the microbial communities of mice that received L. fermentum CRL1446 may be 

































































due to the increased release of FA in the gut, which would have a positive impact on individuals at 
risk of MS.
Firmicutes were dominated by Clostridiales, mainly by Ruminococcaceae family (Figure 8B). 
Overall, the most abundant group was an unclassified group of Clostridiales (Control: 7.30%; MS: 
20.50%; MS+Lf: 20.65%). Within the Ruminococcaceae family the genus Oscillospira prevailed in 
all groups of mice evaluated (Control: 1.70%; MS: 15.85%; MS+Lf: 5.35%). The Lachnospiraceae 
family was also present, but its abundance was low in all the groups evaluated (Control: 1.25%; 
MS: 2.60%; MS+Lf: 1.20%). With respect to the genus Lactobacillus (Lactobacillales family), a 
higher proportion was found in the MS+Lf group (1.95%) compared with the Control (0.25%) and 
MS (0.35%) groups (Figure 8B). In the present study it was found that Lachnospiraceae abundance 
was approximately 2-fold higher in MS group compared to Control and MS+Lf groups (Figure 8B). 
Other researches showed that Lachnospiraceae are more abundant in infants of overweight 
mothers65 and in obese subjects66 and it has also been shown that they positively correlate with 
epididymal adipose tissue67. Moreover, enrichment of specific Lachnospiraceae was reported in 
human studies with diets supplemented with whole grain barley68 and wheat bran69. Regarding the 
genus Lactobacillus (family Lactobacillaceae), previous studies conducted by our research group in 
a murine model demonstrated that a calorie restricted diet increases its abundance, and that the 
administration of L. fermentum CRL1446 to mice subjected to caloric restriction, would allow this 
bacteria to colonize the large intestine with the consequent increase in FE activity in intestinal 
mucosa and content70. A similar effect was observed in animals from MS+Lf group, in which the 
proportion of Lactobacillus was higher (Figure 8B), probably because the prolonged administration 
time of L. fermentum CRL1446 allowed intestinal colonization, altering the microbiota and causing 
increased release of FA from bran fibers; however, more studies of species and strain identification 
are required. Santacruz et al.71 evaluated the influence of an obesity treatment program 
(intervention based on an energy‐restricted diet and regular physical activity) on the gut microbiota 

































































and body weight of overweight adolescents, observing that in the high weight–loss group, 
Lactobacillus group counts increased.
The phylum Bacteroidetes was dominated by Bacteroidales whose family and genus could not be 
determined precisely (Control: 29.65%; MS: 15.80%; MS+Lf: 36.85%). It was also found that 
Prevotella genus (family Prevotellaceae) was not present in the MS group, while the abundance in 
Control and MS+Lf groups was 34.9% and 12.45% respectively (Figure 8B). It is known that 
increase in the Prevotella genus facilitates the fermentation of the carbohydrates that escape 
intestinal digestion and increases the production of SCFA72. Nadal et al.73 reported shifts in 
microbiota associated with weight loss in obese adolescents which included increased proportions 
of Bacteroides-Prevotella. 
Regarding the phylum Proteobacteria, the genus Desulfovibrio was predominant, a much higher 
relative abundance being observed in the MS group (7.35%) compared to the Control group 
(1.25%). Administration of L. fermentum CRL1446 allowed to maintain lower levels of 
Desulfovibrio in the MS+Lf group (4.05%) (Figure 8 A and B). Larsen et al. 74 determined the 
composition of intestinal microbiota of diabetic people and observed that the occurrence of diabetes 
correlated with high Proteobacteria levels compared to healthy individuals. Likewise, Zhang et al.55 
reported an enrichment of sulfatereductive populations such as Desulfovibrio in obese subjects. In a 
study performed by Parker et al.75, it was found that Proteobacteria abundance was significantly 
lower in obese mice group fed with HFD and treated with probiotics (Lactobacillus curvatus 
HY7601 and Lactobacillus plantarum KY1032) compared to mice receiving HFD and placebo.
4. Conclusion 
Our results showed that animals fed with HFD+WB and that jointly received L. fermentum 
CRL1446 hydrolyzed bran fiber more efficiently, so that their metabolic status of improved with 
respect to their MS pairs that did not receive the probiotic strain.

































































There is a close relationship between the gut microbiota composition, intestinal FE activity, 
metabolites derived from FA, SCFA and hydrolysis of the fiber contained in foods. The oral 
administration of L. fermentum CRL1446 increased intestinal FE activity improving the 
biochemical markers of MS and the oxidative status of mice fed with HFD+WB for 14 weeks. 
Modulation of the intestinal microbiota composition through a diet that includes wheat bran fiber 
along with a FE producing probiotic strain, such as L. fermentum CRL1446, or its metabolic 
products/byproducts (postbiotics) represent a promising nutritional strategy to prevent or modify the 
risk of MS and associated metabolic disorders.
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Figure 1: A: Representative photomicrographs of epididymal adipose tissue at 14 weeks. The 
histological sections were stained with hematoxylin-eosin and the images were captured with Carl 
ZEISS microscope with 40x magnification. (A) Control group, (B) MS group, (C) MS + Lf group. 
B: Abundance of adipocytes (%) according to their size (µm2) in mice fed for 14 weeks. Data 
represent mean ± SE (standard error) of n=8 mice per group. The statistical difference was 
determined using Tukey’s test with P<0.05. Values with different letters differ significantly in each 
area range
Figure 2: Representative photomicrographs of liver of mice at week 14. The histological sections 
were stained with hematoxylin-eosin and the images were captured with Carl ZEISS microscope 
with 200x magnification. (A) Control group, (B) MS group, (C) MS+Lf group. The arrows indicate 
some alterations observed in MS group (lipid drops and binucleation).
Figure 3: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) concentrations 
(U/L). Data represent mean ± SE (standard error) of n=8 mice. Statistical differences were 
determined using Tukey’s test with P<0.05. Values with different letters differ significantly.
Figure 4: A: Glucose tolerance curves at week 14 in () Control group, () MS group and () 
MS+Lf group. B: Areas under the curve (AUC) at week 14. Data represent mean ± SE (standard 
error) of n=8 mice. Statistical differences were determined using Tukey’s test with P<0.05. (*) 
indicate statistical differences with respect to the control group. In figure B, values with different 
letters differ significantly.
Figure 5: A: Oral sucrose tolerance curves at week 14 in () Control group, () MS group and () 
MS+Lf group. B: Areas under curve. Data represent mean ± SE (standard error) of n = 8 mice. 
Statistical differences were determined using Tukey’s test with P <0.05. In figure A the asterisks 

































































(*) indicate differences statistics regarding the control group. In figure B values with different 
letters differ significantly.
Figure 6: Concentration of short chain fatty acids (SCFA) produced in colon contents at week 14 
of feeding. Mice received normal diet (Control group), HFD+WB (MS group), HFD+WB 
supplemented with L. fermentum CRL1446 (MS+Lf group). The dose of administration of the 
strains was 108 CFU/day/mouse. Data represent mean ± SE (standard error) of n=8 mice. The 
statistical difference was determined using Tukey’s test with P<0.05. Values with different letters 
differ significantly for each acid evaluated.
Figure 7: Weighted Unifrac-based PCoA analysis of gut microbiota (beta diversity) via 16S rRNA 
sequencing of mice fed for 14 weeks with normal diet (Control group), HFD+WB (MS group) and 
HFD+WB supplemented with Lactobacillus fermentum CRL1446 (MS+Lf group).
Figure 8: Relative abundance of intestinal bacterial communities in mice fed for 14 weeks with 
normal diet (Control group), HFD+WB (MS group) and HFD+WB supplemented with 
Lactobacillus fermentum CRL1446 (MS+Lf group). The figures show the taxonomic categories for 
the different groups evaluated. A: phylum. B: order, family and bacterial genus.
































































Table 1: Body weight gain, food efficiency ratio, adiposity index, and leptin levels. 
Groups
Control MS MS+Lf
Body weight gain (g) 12.90±0.77b 20.44±1.38a 13.92±0.42b
Food efficiency ratio 0.03±0.001b 0.05±0.004a 0.03±0.001b
Adiposity index 2.20±0.16c 4.70±0.21a 3.00±0.20b
Leptin (ng/mL) 0.98±0.17c 6.65±1.07a 1.87±0.16b
Data are expressed as mean ± SE (standard error), n=8 per group. Values with different superscript letters in 
the same row are significantly different (P<0.05) as assessed by Tukey’s test. Control, mice receiving normal 
diet; MS (Metabolic syndrome), mice receiving HFD+WB diet; MS+Lf, mice receiving HFD+WB diet and 
L. fermentum CRL1446. 
















































































































































































TNF-α 5.42±1.69c 36.56±6.60a 19.80±1.50b
IFN- γ 1.34±0.41a 14.34±2.91a 5.68±0.78c
IL-6 2.98±1.09c 18.02±2.06a 10.86±1.79b
IL-10 223.50±43.60a 75.81±14.56c 114.60±15.14b
Data are expressed as the mean ± SE (standard error), n=8 per group. Values with different superscript 
letters in the same row are significantly different (P<0.05) as assessed by Tukey’s test. Control, mice 
receiving normal diet; MS (Metabolic syndrome), mice receiving HFD+WB diet; MS+Lf, mice receiving 
HFD+WB diet and L. fermentum CRL1446.



































































































































































































































Table 3: Plasma lipids and cardiovascular risk indicators
GroupsPlasma lipids 
(g/L) Control MS MS+Lf
Triglyceride 0.27±0.02c 0.43±0.03a 0.35±0.02b
Total cholesterol 0.66±0.02b 0.88±0.02a 0.65±0.03b
LDL-cholesterol 0.56±0.02b 0.71±0.01a 0.52±0.02b
HDL-cholesterol 0.16±0.01b 0.12±0.01a 0.16±0.01b
Cardiovascular 
risk indicators
LDL/HDL 3.57±0.34b 5.81±0.25a 3.34±0.22a
Triglyceride/HDL 1.73±0.11c 3.49±0.15a 2.26±0.21b
Atherogenic index 3.18±0.43b 6.19±0.52a 3.16±0.64b
AIP 0.24±0.04c 0.54±0.06a 0.35±0.06b
Data are expressed as the mean ± SE (standard error), n=8 per group. Values with different 
superscript letters in the same row are significantly different (P<0.05) as assessed by Tukey’s test. 
Control, mice receiving normal diet; MS (Metabolic syndrome), mice receiving HFD+WB diet; 
MS+Lf, mice receiving HFD+WB diet and L. fermentum CRL1446.  Atherogenic index: (total 
cholesterol – HDL-cholesterol)/ HDL-cholesterol. AIP: Atherogenic Index of Plasma = Log 
(TG/HDL).












































































































































































Table 4: Plasma glucose, insulin levels and HOMA-IR
Data are expressed as mean ± SE (standard error), n=8 per group. Values with different superscript 
letters in the same row are significantly different (P<0.05) as assessed by Tukey’s test. Control, mice 
receiving normal diet; MS (Metabolic syndrome), mice receiving HFD+WB diet; MS+Lf, mice 
receiving HFD+WB diet and L. fermentum CRL1446.
Groups
Control MS MS+Lf
Glucose (mmol/L) 3.96±0.46b 7.79±0.91a 4.12±0.23b
Insulin (μU/mL) 8.69±0.69b 12.59±0.85a 8.84±0.75b
HOMA-IR 1.53±0.27b 4.36±0.41a 1.62±0.29b
















































































































































































Table 5: Intestinal feruloyl esterase, glutathione peroxidase and glutathione reductase 
activities and TBARS levels
IFE: intestinal feruloyl esterase, GPx: glutathione peroxidase, GR: glutathione reductase, TBARS: 
thiobarbituric acid reactive substances. Values are expressed as mean ± SE (standard error), n=8 per group. 
Values with different superscript letters in the same row are significantly different (P<0.05) as assessed by 
Tukey’s test. Control, mice receiving normal diet; MS (Metabolic syndrome), mice receiving HFD+WB diet; 





IFE (U/g) 1255.60±50.27a 733.00±82.90c 1074.00±170.14b
GPx (U/g) 34.15±0.97b 30.50±0.73c 41.84±3.12a
GR (U/g) 53.91±1.30b 45.90±1.94c 75.72±2.74a
TBARS (nmol/g) 32.42±6.60b 47.94±4.54a 32.32±2.71b
































































Table 6: Detection of FA-derived metabolites in colon contents of mice fed for 14 weeks by HPLC-MS. 
The mass/charge ratios (m/z) and retention times (RT) for each compound are shown. FA: ferulic acid; DHF: 
dihydroferulic acid; DHPPA: dihydroxyphenylpropionic acid, HPPA: hydroxyphenylpropionic acid and BA: 
benzoic acid. The metabolites detected are shown for the 3 groups of mice tested (n=3 each). (-): metabolite 










FA 12.55 193.0 - - -
DHF 8.26 195.1 + + +
DHPPA 7.36 181.1 + + +
HPPA 8.56 165.1 ++ + +++
BA 13.2 121.0 - - -































































































































































Table 7: Alpha diversity metrics
Groups 
Metric Control MS MS+Lf
Shannon 5.38±0.46a 6.29±0.12b 6.28±0.32b
Chao 1 297.98±23.82a 267.06±4.04a 330.36±0.74b
Observed OTUs (Species) 274.10±28.50a 255.65±0.75a 313.75±7.95b
PD whole tree 20.86±0.91a 19.28±0.30a 22.80±0.12b
Chao1, Shannon’s diversity and phylogenetic diversity (PD whole tree) of colon contents of mice fed for 14 
weeks. Data are expressed as mean ± SE (standard error), n=3 per group. Values with different superscripts, 
within the same row, are significantly different (P< 0.05).
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